Liu Yibo, Ma Wenjing, Fu Hui, Zhang Zhe, Yin Yanyan, Wang Yongchun, Liu Wei, Yu Shaohong, Zhang Zhongwen
Department of Endocrinology and Metabology, Rehabilitation Hospital, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, The Third Affiliated Hospital of Shandong First Medical University, Jinan, China.
Rehabilitation Hospital, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Front Pharmacol. 2024 Feb 26;15:1235639. doi: 10.3389/fphar.2024.1235639. eCollection 2024.
Some studies have proved that polyethylene glycol loxenatide (PEG-Loxe) has significant effects on controlling blood glucose and body weight in patients with type 2 diabetes mellitus (T2DM), but there is still some controversy over the improvement of blood lipid profiles (BLP) and blood pressure (BP), and more evidences are needed to verify such effects. Therefore, this study was conducted to provide a comprehensive evaluation of the efficacy of PEG-Loxe in improving blood glucose (BG), BLP, BP, body mass index (BMI), and body weight (BW) in patients with T2DM for clinical reference. Randomized controlled trials (RCT) in which PEG-Loxe was applied to treat T2DM were retrieved by searching PubMed, Cochrane Library, Embase, Medline, Scopus, Web of Science, China National Knowledge Infrastructure, China Scientific Journal, Wanfang Data, and SinoMed databases. Outcome measures included BG, BLP, BP, BMI, and BW. RevMan 5.3 software was used to perform data analysis. Eighteen trials were identified involving 2,166 patients. In experimental group 1,260 patients received PEG-Loxe alone or with other hypoglycemic agents, while in control group 906 patients received placebo or other hypoglycemic agents. In the overall analysis, PEG-Loxe significantly reduced the levels of glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-h postprandial blood glucose (2-h PBG), BMI, and BW compared with control group. However, it had no obvious effect on total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), systolic blood pressure (SBP), and diastolic blood pressure (DBP). PEG-Loxe has better hypoglycemic effects compared with placebo in patients with T2DM, but could not significantly improved TG, LDL-C, HDL-C, SBP, and DBP. And the combination of conventional hypoglycemic drugs (CHD) and PEG-Loxe could more effectively improve the levels of HbA1c, FPG, 2-h PBG, TC, TG, BMI, and BW compared with CHD in T2DM patients. www.inplasy.com, identifier INPLASY202350106.
一些研究证明，聚乙二醇洛塞那肽（PEG-Loxe）对2型糖尿病（T2DM）患者的血糖和体重控制有显著效果，但在改善血脂谱（BLP）和血压（BP）方面仍存在一些争议，需要更多证据来证实此类效果。因此，本研究旨在全面评估PEG-Loxe对T2DM患者血糖（BG）、BLP、BP、体重指数（BMI）和体重（BW）的改善效果，以供临床参考。通过检索PubMed、Cochrane图书馆、Embase、Medline、Scopus、Web of Science、中国知网、中国科学期刊、万方数据和中国生物医学文献数据库，获取应用PEG-Loxe治疗T2DM的随机对照试验（RCT）。观察指标包括BG、BLP、BP、BMI和BW。使用RevMan 5.3软件进行数据分析。共纳入18项试验，涉及2166例患者。在实验组中，1260例患者单独接受PEG-Loxe或与其他降糖药物联合使用，而在对照组中，906例患者接受安慰剂或其他降糖药物。在总体分析中，与对照组相比，PEG-Loxe显著降低了糖化血红蛋白（HbA1c）、空腹血糖（FPG）、餐后2小时血糖（2-h PBG）、BMI和BW水平。然而，它对总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、收缩压（SBP）和舒张压（DBP）没有明显影响。与安慰剂相比，PEG-Loxe对T2DM患者具有更好的降糖效果，但不能显著改善TG、LDL-C、HDL-C、SBP和DBP。与传统降糖药物（CHD）相比，CHD与PEG-Loxe联合使用能更有效地改善T2DM患者的HbA1c、FPG、2-h PBG、TC、TG、BMI和BW水平。www.inplasy.com，标识符INPLASY202350106。
